Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fertifolin is an oral dietary supplement developed by Valenta Pharmaceuticals, specifically formulated to support female reproductive health and fertility. It consists of a combination of myo-inositol and folic acid (Vitamin B9). Myo-inositol serves as a second messenger for insulin and follicle-stimulating hormone (FSH), helping to regulate glucose metabolism and improve oocyte quality, which is particularly beneficial for women with polycystic ovary syndrome (PCOS). Folic acid is a crucial nutrient for DNA synthesis and repair, and its supplementation is standard practice to prevent neural tube defects and support healthy fetal development during pregnancy. Fertifolin is typically used to prepare the body for conception and to support the early stages of pregnancy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Fertifolin.